Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review

Detalles Bibliográficos
Autores principales: Lundy, Joanne, McKay, Owen, Croagh, Daniel, Ganju, Vinod
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830512/
https://www.ncbi.nlm.nih.gov/pubmed/35085003
http://dx.doi.org/10.1200/PO.21.00437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830512/
https://www.ncbi.nlm.nih.gov/pubmed/35085003
http://dx.doi.org/10.1200/PO.21.00437

Ejemplares similares